You are here

  • Home
  • Archive
  • Volume 68, Issue 11
  • The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

Citation Tools

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Schiff M, Pritchard C, Huffstutter JE, et al
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
Annals of the Rheumatic Diseases 2009;68:1708-1714.